Text Size

Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

This study is currently recruiting participants.
Verified December 2012 by Alberta Health Services
Sponsor:
Information provided by (Responsible Party):
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT01428739
First received: October 21, 2010
Last updated: December 10, 2012
Last verified: December 2012
History of Changes
  Purpose

Correlation between MRS and Tumor Response Therapy in Breast Cancer.


Condition Intervention
Breast Cancer
 Device: MRS

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alberta Health Services:

Primary Outcome Measures:
  • MRS Correlation with Treatment Response [ Time Frame: Up to One Year ] [ Designated as safety issue: Yes ]
    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment


Secondary Outcome Measures:
  • Correlation with Tumor Stage [ Time Frame: Up to One year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 10
Study Start Date: December 2007
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: MRS
    Procedure
    Other Name: Philips 3 Tesla MRI Scanner
Detailed Description:

Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01428739

Contacts
Contact: Nadeem Pervez, MBBS, FFRRCSI, FRCPC 780-432-8517 nadeem.pervez@albertahealthservices.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Nadeem Pervez, MBBS, FFRRCSI, FRCPC     780-432-8517     nadeem.pervez@albertahealthservices.ca    
Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute
  More Information

No publications provided

Responsible Party: Alberta Health Services
ClinicalTrials.gov Identifier: NCT01428739     History of Changes
Other Study ID Numbers: 23701
Study First Received: October 21, 2010
Last Updated: December 10, 2012
Health Authority: Canada: Health Canada

Keywords provided by Alberta Health Services:
cancer
MRS
Treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on June 17, 2013